Table 2 Parameter costs and economic considerations. The estimates were obtained from relevant South African literature for the year 2012

HIV vaccine characteristics

Value

(Range)

Reference

 Coverage

60 %

(40–70)

Assumption

 Price (US$)

12

(2–24)

[47]

 HIV vaccine efficacy

50 %

(30–70)

Assumption

Economics

Value

(Range)

Reference

 Cost discount rate

3.0 %

(0–6 %)

[19]

 Outcome discount rate

3.0 %

(0–6 %)

[19]

 International comparison (ZAR: 1US$)

ZAR 8.21

-

[26]

HIV disease related costs

Distribution

Value

Reference

HIV prevention programme

 HIV vaccine

-

12

[21]

 Vaccine delivery per dose

Gamma

17

[48–52]

 Existing prevention programme (incl. HR)

Gamma

65

[49–53]

 Voluntary counselling and testing (VCT) (per test)

Gamma

23

[49, 50]

 Cost of HIV rapid testing

Gamma

2

[49, 50]

 Asymptomatic treatment (not on ART)

Gamma

131

[18, 53]

 Symptomatic treatment (not on ART)

Gamma

137

[18, 53]

 AIDS treatment (not on ART)

Gamma

182

[18, 53]

 Patient on ART (average)

Gamma

424

[18, 23]

ART cost (annual)

 First-line regimen

Gamma

10

[23]

 Second-line regimen

Gamma

27

[23]

 Third-line regimen

Gamma

173

[23]

Laboratory costs (annual)

 First-line regimen (first year)

Gamma

17

[18, 53]

 First-line regimen (subsequent years)

Gamma

46

[18, 53]

 Second-line regimen

Gamma

46

[18, 53]

 Third-line regimen

Gamma

92

[18, 53]

 Not on ART

Gamma

65

[53]